Cleveland Clinic Chief Pharmacy Officer: Time to Pass the CREATES Act

Wednesday November 14, 2018

Scott Knoer, M.S., Pharm.D, serves as Chief Pharmacy Officer for the Cleveland Clinic, one of the largest hospitals nationwide. In an October 23 op-ed for The Hill titled “Antidote to rising drug prices languishes on the Hill”, he shared his perspective on rising drug prices and identified one solution in particular that would help bring them down. The solution, as he believes it, is for Congress to take action on bipartisan legislation known as the CREATES Act.

Dr. Knoer writes: “One simple, effective tool is sitting right in front of Congress and the White House. It’s called the CREATES Act of 2018. It’s bipartisan. It’s taking aim at drug prices by restoring true competition to the marketplace. And the Congressional Budget Office scored it as a $3.9 billion money-saver.”

The Biosimilars Council agrees with Mr. Knoer’s conclusion and is in support of the CREATES Act (S. 974/H.R. 2212) to be taken up by Congress and ultimately enacted into law. As Dr. Knoer notes, “The CREATES Act has easily passed the Senate Judiciary Committee, with support from both the right and left. If we really want to put American patients first, let’s pass the act and end anti-competitive pharmaceutical practices that are keeping drugs prices high.”

The CREATES Act, if passes, would seek to stop brand company actions that limit biosimilars developers’ access to samples for testing. Securing access to samples is critical to demonstrating biosimilarity, which is essential to biosimilar approval by the FDA. Without access to samples, biosimilars face steeper hurdles to approval, ultimately limiting patient access to essential medicines.

Dr. Knoer’s op-ed comes as National Pharmacist Month comes to a close. Read how pharmacists are supporting biosimilars.

Click here to read the full op-ed.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.